Carregant...
“Economic Evidence on Identifying Clinically Actionable Findings with Whole Genome Sequencing: A Scoping Review”
BACKGROUND: The American College of Medical Genetics (ACMG) recommends that mutations in 56 genes for 24 conditions are clinically actionable, and should be reported as secondary findings after whole genome sequencing (WGS). Our aim was to identify published economic evaluations of detecting mutatio...
Guardat en:
| Publicat a: | Genet Med |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4654986/ https://ncbi.nlm.nih.gov/pubmed/25996638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/gim.2015.69 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|